Form 4: CEO John Oyler Reports Equity Transactions at BeOne

CEO John Oyler acquired restricted share units and stock options while selling shares to cover tax obligations.

Summary

• CEO John Oyler acquired 177,931 restricted share units (RSUs) on June 11, 2026.
• CEO John Oyler was granted 344,669 stock options with an exercise price of $20.81.
• The reporting person sold 1,949 American Depositary Shares (ADS) to satisfy mandatory tax withholding requirements related to RSU vesting.
• The ADS sales occurred at weighted average prices ranging from $256.2282 to $258.81 per share.
• Following these transactions, the CEO maintains a direct beneficial ownership of 5,697,649 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine executive compensation and tax compliance.

Positives

• The CEO continues to hold a significant equity stake in the company, aligning interests with shareholders.
• The acquisition of additional equity through RSUs and options indicates long-term commitment to the company's growth.

Negatives

• The sale of shares, even for tax purposes, reduces the direct holdings of the CEO.

Risks

• Vesting of equity awards is subject to continued service requirements.
• Market price volatility of American Depositary Shares could impact the value of future equity-based compensation.

Future Outlook

The equity awards vest over a four-year period, signaling management's expectation of continued service and long-term operational focus.

Management Comments

• The reporting person has provided or undertakes to provide full information regarding the number of shares sold at each separate price upon request.

Industry Context

StockSavvy.ai notes that executive equity grants and tax-related sales are standard practices in the biotechnology sector, reflecting typical compensation structures for high-level leadership.

Comparison to Industry Standards

• The use of mandatory tax withholding sales is a standard corporate governance practice for executives in the pharmaceutical and biotech industries.
• The four-year vesting schedule for equity awards is consistent with industry benchmarks for executive retention.

Related Party Transactions

• The reporting person disclaims beneficial ownership of shares held by the P&O Trust, a grantor retained annuity trust, Oyler Investment LLC, and The John Oyler Legacy Trust.

Stakeholder Impact

• Shareholders should view the CEO's continued significant ownership as a sign of stability.

Next Steps

• Continued service of the CEO to satisfy vesting requirements for the new RSU and option grants.

Key Dates

Keywords

BeOne Medicines, John Oyler, Insider Trading, Form 4, Equity Compensation, Biotech